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INTRODUCTION With established applications of next-generation sequencing in in-
herited diseases and oncology, clinical laboratories are evaluating the use of metag-
enomics for identification of infectious agents directly from patient samples, to aid
in the diagnosis of infections. Metagenomic next-generation sequencing for infec-
tious diseases promises an unbiased approach to detection of microbes that
does not depend on growth in culture or the targeting of specific pathogens. How-
ever, the issues of contamination, interpretation of results, selection of databases
used for analysis, and prediction of antimicrobial susceptibilities from sequencing
data remain challenges. In this Point-Counterpoint, Steve Miller and Charles Chiu dis-
cuss the pros of using direct metagenomic sequencing, while Kyle Rodino and Me-
lissa Miller argue for the use of caution.
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POINT
The fundamental role of the clinical microbiology laboratory is to detect, to identify,and to characterize pathogens that cause infections in patients, to guide patient
management. Over the years, the methods in use have changed dramatically and now
include a variety of culture-based approaches, visualization by microscopy, antigen
detection, serological methods, and molecular detection. Each of these methods has its
strengths and weaknesses and detects a defined spectrum of organisms that are
potentially able to be cultivated and/or detected. Improvements to these microbiolog-
ical assays, such as enhanced culture media and multiplex PCR syndromic panels, have
expanded the range of organisms detectable by the laboratory. Along the way, clinical
microbiologists have had to adapt their techniques and understand the benefits and
limitations of new technologies in order to provide the most accurate information to
guide treatment decisions.
The advent of high-throughput sequencing methods, known as next-generation
sequencing (NGS), allows the simultaneous characterization of millions of individual
DNA fragments (or cDNA fragments from RNA), facilitating genome assembly and
metagenomic analysis. The ability to broadly detect all classes of organisms directly
from patient samples is the major advantage of metagenomic NGS (mNGS) methods
over targeted methods such as multiplex PCR panels. However, significant concerns
exist regarding the performance, validity, and clinical significance of the organisms
detected using mNGS. These substantial challenges need to be addressed during the
clinical development of mNGS assays for pathogen detection. In our experience, these
challenges can be overcome if the laboratory is willing to commit the needed resources
and has the appropriate expertise, making it feasible for clinical laboratories to perform
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mNGS for patient testing (1). Furthermore, the clinical benefits of mNGS patient testing 
in facilitating the diagnosis of neurological infections and informing treatment deci-
sions have already been demonstrated in a prospective, multisite, diagnostic trial (2). In 
that study of 204 patients with undiagnosed meningitis, encephalitis, and/or myelitis, 
13 (22%) of 58 infectious cases were diagnosed by mNGS testing alone, and actionable 
clinical management and treatment decisions were made on the basis of mNGS results 
in more than one-half of those cases. The broad applicability of mNGS methods in 
research laboratories across a variety of infectious syndromes and sample types has 
also been illustrated in a growing number of case reports and small case series (3). 
Laboratories have continued to develop and to validate mNGS assays to address a 
variety of infectious disease syndromes, such as sepsis and pneumonia, demonstrating 
high analytical sensitivity and detection of more organisms thought to be pathogenic 
than are detected by conventional methods (4, 5).
Reference and commercial laboratories are now offering mNGS assays in laborato-
ries certified in accordance with the CLIA program, for patient diagnosis using selected 
sample types. There appears to be substantial demand from providers and patients for 
mNGS testing, likely based on the hope of uncovering previously undiagnosed infec-
tious disease. In order to support the use of mNGS testing, analytical and clinical 
validation studies are needed. Validation of an unbiased mNGS assay is a challenging 
task, since all organism species and subtypes are potentially detectable. This also poses 
regulatory challenges, as it would be impractical to obtain and to test more than a 
handful of cases for each infectious organism for purposes of validation. Our solution 
has been to adopt a “representative organism” approach, using individual species to 
serve as models for detection of other pathogens within that category (e.g., DNA 
viruses, RNA viruses, Gram-negative bacteria, Gram-positive bacteria, yeasts, and molds)
(1), with the expectation that similar organism types can be expected to behave 
similarly in the assay. A list of detected species, with the findings confirmed by 
alternative laboratory testing, can be maintained and expanded over time to establish 
the spectrum of organisms that can be reliably tested for and reported by the mNGS 
assay. A model for this approach may be the clinical validation of matrix-assisted laser 
desorption ionization–time of flight mass spectrometry-based assays for bacterial 
identification, for which reference databases of reportable organisms may be expanded 
with additional confirmed strains over time.
A significant potential limitation to the use of mNGS assays for infectious disease 
diagnostics is the possibility of false-positive results due to contamination. This issue is 
not restricted to mNGS testing; in fact, microbiology laboratories are very familiar with 
contamination, especially for culture-based and PCR assays, and have developed 
specific protocols to deal with contamination events. Sources of “contamination” in 
mNGS results include detection of normal human body flora or background contami-
nating organisms in laboratory reagents or the environment, as well as bioinformatic 
analysis or database errors, such as misannotations, that can lead to organism misiden-
tification. A salient example is the discovery of xenotropic murine leukemia virus-
related virus (XMRV) and its initial apparent association with chronic fatigue syndrome 
(6). Although XMRV was later shown to be a laboratory-derived recombinant virus not 
present in the human population and the association with chronic fatigue syndrome 
was disproven, there was emerging demand for clinical testing and even treatment 
decision-making on the basis of XMRV status. However, we have found that risk 
mitigation strategies can be effective in avoiding misinterpretation of mNGS results due 
to contamination; strategies include (i) addition of interpretive notes based on guid-
ance from expert laboratory physicians, (ii) confirmation of organisms newly identified 
by mNGS using alternative methods, (iii) implementation of a contamination-
monitoring strategy, such as a dedicated contaminant reference database, and (iv) 
institution of a real-time teleconference hosted by experienced laboratory directors and 
subspecialist physicians (clinical microbial sequencing board) to discuss results in 
clinical context with treating physicians (2). Ultimately, implementation of these strat-
egies is the responsibility of the clinical laboratory providing mNGS testing, to ensure 
that mNGS results are used appropriately to guide patient management and care.
With respect to the adoption of mNGS testing in clinical laboratories, the guidelines 
and standards for clinical NGS testing that were initially developed for oncology and 
inherited disease applications (7, 8) have been adapted to infectious disease diagnostic 
performance evaluation (9). Conceptually, mNGS assays for infectious diseases are 
similar to oncological and noninvasive prenatal testing NGS assays, which are currently 
FDA approved and in widespread use, in their ability to detect unlimited numbers of 
sequence variants, and sample-processing steps in generating and analyzing sequence 
data overlap significantly. Thus, we may be able to leverage the requirements for 
testing and reporting of results for clinical mNGS assays that have already been 
established by our colleagues in other fields of medicine.
Quality control (QC) for mNGS assays is critical to ensure accurate performance. 
Because these are complex multistep tests, several QC metrics are required, including 
sample controls, external controls, internal controls, library quality metrics, sequencing 
quality metrics, and contamination controls. Each of these can be defined by the 
laboratory with acceptable criteria to ensure that sample quality and run quality are 
adequate and errors have not occurred during the processing steps. Although complex, 
the establishment and monitoring of robust mNGS QC metrics have been successfully 
adapted to the clinical microbiology laboratory setting (1, 10).
Analysis of mNGS data relies on the ability of bioinformatic pipelines to accurately 
classify sequence reads using established databases. Several bioinformatic pipelines 
have been developed for metagenomic analysis (11). Methods to filter out database 
errors and inaccurate sequence matches to avoid inadvertent misclassification are often 
necessary, especially when noncurated databases are used. Such methods include 
computational host subtraction, masking or removal of known errors, taxonomic 
classification, and filtering of sequence reads to ensure accuracy using alternative 
alignment programs. Another challenge is that application and validation of bioinfor-
matic tools for mNGS analysis generally require specialized computational expertise. 
However, these challenges have been successfully addressed in the field of metag-
enomics with the development of easy-to-use, automated software with graphical user 
interfaces, including platforms such as SURPI, Taxonomer, CosmosID, and OneCodex. 
In addition, the recent availability of databases that have been extensively curated for 
accuracy, such as FDA-ARGOS (12), has been useful in ensuring that mNGS results are 
reliable and correct.
The interpretation of mNGS results in clinical context is a key part of the use of 
MNGS testing in patient management. An advantage of this unbiased approach is the 
ability to diagnose rare infections, such as hepatitis E virus-associated meningoenceph-
alitis (13). From a public health perspective, mNGS testing can provide evidence of 
newly emerging or reemerging pathogens. For example, our clinical mNGS testing of 
cerebrospinal fluid resulted in identification of the first human case of St. Louis 
encephalitis virus in California since 1986 (14). Unusual organism detections such as this 
can be reported to public health agencies, which may be able to assist in follow-up 
confirmatory testing.
Studies regarding the clinical utility and cost-effectiveness of mNGS assays for 
pathogen detection are lacking, making this area one in need of further investigation. 
While mNGS testing is expensive, relative to most traditional microbiological tests, the 
incremental costs of testing are minimal, compared to the costs of intensive care unit 
stays or invasive diagnostic biopsy procedures or even relative to the myriad diagnostic 
tests that are ordered for complex cases. Thus, if even a small percentage of mNGS test 
results demonstrate a causative pathogen, with effects on subsequent patient care, 
substantial cost savings for health systems overall are likely. Since mNGS testing for 
infectious disease diagnosis lacks a specific CPT code, reimbursement for direct testing 
costs is limited; therefore, the cost impact is best seen in the context of all patient 
management costs until further cost-benefit data are available to guide reimbursement 
decisions.
Steve Miller and Charles Chiu
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COUNTERPOINT
With great power comes great responsibility.
—Uncle Ben in Spider-Man
The power of untargeted metagenomic next-generation sequencing (mNGS) isundeniable. As molecular technologies continue to evolve, it is tempting to adopt
them quickly in the diagnostic laboratory. In the case of mNGS, there are a number of 
analytical and practical challenges that must be addressed before mNGS becomes a 
widely adopted routine diagnostic test in the clinical microbiology laboratory. We think 
that current limitations in test performance, a lack of standardized methods for mNGS, 
and limited guidance on clinical utility make this method less useful and less accessible 
than it needs to be for use in routine clinical microbiology laboratories.
The general perception, particularly among medical providers, is that mNGS is 
exquisitely sensitive, such that it will yield a result when all other diagnostic test results 
are negative. While mNGS is more analytically sensitive than smears or cultures, in most 
cases it is not as sensitive as targeted nucleic acid amplification methods, in part due 
to the vast amount of human DNA/RNA that is sequenced and removed during 
computational analysis. Analytical sensitivity may also vary by pathogen (1). Additional 
factors affecting mNGS sensitivity include the timing of specimen collection, specimen 
stability, and source/cellularity, as well as methodological variables such as the extrac-
tion method, library preparation, and data analysis (1, 2). The current sensitivity of 
mNGS prohibits the technology from becoming a frontline diagnostic test. Methods 
that enable host nucleic acid depletion should offer improved sensitivity for the 
agnostic detection of infectious disease etiologies (3).
The specificity of mNGS testing can be affected during every testing phase (pre-
analytical, analytical, and postanalytical), because specimens can become contami-
nated with nucleic acids from microorganisms that are not the cause of the patients’ 
infections. Specimens are collected in a wide range of collection devices and locations, 
which introduces variables that might affect specificity, including microbial DNA found 
in sterile collection devices and exogenous DNA introduced by the environment or 
personnel during specimen collection. During the technical performance of mNGS, 
negative controls and genome coverage controls can help identify exogenous DNA 
from reagents or laboratory processes. With some Illumina platforms, sequence reads 
can be assigned to the wrong index (i.e., index hopping) during the demultiplexing 
process, which can lead to false-positive results if not controlled for and filtered out 
during analysis (4). Additional specificity challenges arise during data analysis and 
sequence alignment, including misclassification, database errors, and identification of 
DNA not derived from the patient sample.
While analytical specificity can be addressed during verification and through imple-
mentation of appropriate controls, a greater concern with mNGS testing is its clinical 
specificity. Is the detected sequence specific to the patient’s current disease process?
Do we understand the half-life of pathogen nucleic acids or the impact of latency, and 
does this differ among hosts? How many reads (i.e., what level of positivity) are required
to report a positive finding, and is this different for various disease processes or hosts?
It is important that results of mNGS testing be scrutinized with an understanding of the 
potential for false-positive results.
There are not yet FDA-cleared or approved tests using mNGS for infectious diseases. 
Therefore, each clinical laboratory must develop and validate a laboratory-developed 
test (LDT) that includes extraction, library preparation, sequencing, and analysis pipe-
line. Optimization and verification of the performance of the system, across diverse 
potential pathogens, present a new level of complexity, compared to targeted molec-
ular techniques. Any change to a component of the LDT must be reverified, which 
makes the use of open source pipelines particularly challenging, since it is critical for 
databases to remain up to date. For routine implementation, mNGS testing will need to 
be in a closed system that has undergone regulatory review.
During validation, thresholds must be set for the minimum number and quality of 
reads for analysis, the ratio of organism reads from the sample to reads present in the 
negative control, and the number of reads required for a reportable result. Once 
thresholds are established, clinical validation will likely involve testing of known 
positive and/or negative patient samples. The majority of validation studies use resid-
ual, frozen specimens and not prospectively collected, fresh samples, which limits the 
assessment of specimen stability and temporal variability. Unexpected results will 
almost certainly be encountered and should be adjudicated by an additional method, 
an endeavor that can be problematic from both cost and feasibility standpoints (1).
Result interpretation should be carefully considered during clinical validation. Unlike 
traditional culture-based methods, for which decades of data and clinical correlations 
have led to established procedures for interpretation, the paucity of prospective 
analyses and clinical trials for mNGS testing leaves interpretation open. While the 
interpretation of results may be more straightforward for normally sterile sources, 
nonsterile sources pose additional challenges, such as the normal microbiome and 
asymptomatic carriage. Therefore, interpretation of mNGS results in the clinical context 
will likely require significant manual effort. Committee review of results (similar to a 
tumor board) seems like a responsible approach, but routine laboratories may find 
assembling such expertise a limiting factor.
A number of practical challenges also exist, limiting the broad implementation of 
mNGS. While advancements in technology have shortened the time needed to perform 
mNGS, the current turnaround time (TAT) (in-house, 2 days to 1 week; send out, 2 or 
more weeks) limits routine use of mNGS testing, because results may not be available 
within a clinically actionable time frame (2, 5). The achievable TAT is dependent on the 
expected volume of samples. While mNGS is inherently high throughput, the necessary 
number of reads per run may limit the number of samples that can be pooled. If fewer 
samples are multiplexed, then the TAT and cost per test are increased. This alone may 
limit the feasibility of in-house mNGS.
For any clinical laboratory running molecular assays, contamination is always a risk 
and a fear. We attempt to mitigate this risk with quality control, unidirectional work-
flow, and stringent decontamination protocols. With the unbiased detection of mNGS, 
the concern regarding contamination only increases. Exogenous DNA from any source, 
not just that specific to the assay’s target, will appear in the sequencing data. It is likely 
that laboratories will need dedicated space designed specifically for mNGS, allowing 
minimal chance for contamination. Space limitations faced by many clinical laboratories 
make establishing a dedicated mNGS area a challenge.
Data storage and security represent another hurdle to routine use of mNGS. Data 
storage on the terabyte level has not previously been needed in clinical microbiology. 
More than simply storing the data, security must be ensured, because mNGS data 
contain HIPAA-protected patient information (6). This is complicated when open source 
or commercially available cloud-based pipelines are used, requiring the sharing of data 
with entities that are not subject to the same level of regulation as the clinical 
laboratory. The cost of storing and securing the data generated, while complying with 
the requirements of accrediting agencies, should not be understated.
Kyle G. Rodino and Melissa B. Miller
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Finally, the future of reimbursement for diagnostic use of mNGS remains unclear. In 
early 2018, CMS approved reimbursement for the use of NGS in oncology for their 
patients. A number of caveats accompanied this decision, one being that only FDA-
approved/cleared testing was reimbursable, excluding LDTs. This decision, along with 
recent reimbursement challenges for syndrome-based molecular panels, makes for an 
uncertain future.
The power of mNGS is indisputable, providing insight into the microbial composi-
tion of a sample not previously achievable in clinical microbiology. We must work 
responsibly to harness its diagnostic power for the benefit of our patients while 
remaining good stewards of resources, regardless of whether mNGS is performed 
in-house or at a reference laboratory. Quite simply, for broad implementation of 
mNGS testing, industry partners need to develop in vitro diagnostic products for 
infectious disease metagenomics. The majority of laboratories do not have the 
bandwidth for mNGS test development, bioinformatics expertise, or the financial 
investment needed to validate a mNGS LDT ($100,000 in supplies for cerebrospi-
nal fluid mNGS testing) (2).
Currently, the role of mNGS is derived largely from case-level reports of retrospective 
diagnosis and proof-of-principle applications. We need method comparison studies to 
optimize LDTs and to normalize protocols between institutions (2, 7, 8). The develop-
ment of predictive models is needed to improve automated and integrated data 
analysis, providing actionable reports for clinicians. Finally, and most importantly, we 
need to establish the clinical utility of mNGS testing (9). Studies like that by Wilson et 
al. demonstrate the ability of mNGS to detect a potential pathogen not otherwise found 
by conventional methods, providing a diagnosis for an additional 3 to 6% of patients 
(10). However, given the current cost of such assays, broad use coupled with low 
expected return confers a significant financial burden per actionable result. Additional 
well-designed outcome studies will help identify patient populations, clinical syn-
dromes, and specific laboratory test parameters for which mNGS is most likely to 
provide additional diagnostic information. Such guidance will allow targeted use of 
mNGS testing, increasing the expected utility and ensuring that the power of the 
technology is used in the settings most likely to improve patient care (11).
SUMMARY
Points of agreement
1. Direct sequencing of clinical specimens offers the potential for unbiased, rapid
detection of pathogens that may not be viable in culture or detected by
traditional laboratory methods.
2. mNGS testing is not a replacement for conventional microbiological testing, such
as culture and serology.
3. A comprehensive validation for every organism detectable by sequencing is not
possible, requiring new strategies in which representative pathogens are in-
cluded in the validation study as proxies for all other targets.
4. Offering mNGS assays requires a significant financial investment from the labo-
ratory and will necessitate new strategies for laboratory reimbursement.
5. Contamination of mNGS assays is a significant challenge, requiring a well-
designed control strategy that evaluates contamination in all aspects of testing.
Issues to be resolved
1. Determining how pathogenic organisms can be differentiated from commensals
when using sequencing will require new approaches for laboratory consultation
with clinicians.
2. Cost-effectiveness and guidelines on when to perform mNGS need to be devel-
oped.
3. Regulatory hurdles and lack of insurance reimbursement make implementation
of mNGS testing difficult.
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